Related Experiment Videos
Intravenous nitroglycerin for acute myocardial infarction
1Heart and Vascular Institute, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI 48202.
Henry Ford Hospital Medical Journal
|January 1, 1991
Summary
Intravenous nitroglycerin (IV TNG) is safe and offers modest pain relief for acute myocardial infarction. Early administration may reduce infarct size and mortality, especially in heart failure patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Intravenous nitroglycerin (IV TNG) use is rising for acute myocardial infarction (AMI).
- Evidence for IV TNG's clinical benefits in AMI requires synthesis.
Purpose of the Study:
- To review randomized trials assessing the clinical efficacy of IV TNG in acute myocardial infarction.
- To evaluate the safety and effectiveness of IV TNG for chest pain, hemodynamic effects, infarct size, and mortality.
Main Methods:
- Systematic review of seven randomized trials comparing IV TNG with placebo.
- Inclusion of one trial comparing IV isosorbide dinitrate with furosemide.
Main Results:
- Low-dose IV TNG is safe in AMI and provides modest chest pain relief.
- Hemodynamic benefits are most significant in patients with congestive heart failure.
- Limited evidence indicates early IV TNG may reduce infarct size and mortality.
Conclusions:
- IV TNG is a safe adjunctive therapy for acute myocardial infarction.
- Early prophylactic use of IV TNG shows potential for improved clinical outcomes, including reduced infarct size and mortality.
- Further research is warranted to confirm these benefits, particularly regarding optimal dosing and timing.